IRIS
SANTONI, MATTEO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.974
EU - Europa 2.784
AS - Asia 1.459
SA - Sud America 214
AF - Africa 149
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 3
Totale 11.588
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.968
UA - Ucraina 467
SG - Singapore 462
IT - Italia 413
RU - Federazione Russa 392
IE - Irlanda 388
SE - Svezia 381
CN - Cina 316
HK - Hong Kong 308
DE - Germania 256
BR - Brasile 200
TR - Turchia 180
DK - Danimarca 158
CI - Costa d'Avorio 124
FI - Finlandia 111
GB - Regno Unito 99
KR - Corea 91
IN - India 62
FR - Francia 41
EE - Estonia 22
BE - Belgio 18
MA - Marocco 16
PL - Polonia 9
NL - Olanda 8
PK - Pakistan 6
ES - Italia 5
EU - Europa 5
AT - Austria 4
VN - Vietnam 4
AR - Argentina 3
AU - Australia 3
CA - Canada 3
ID - Indonesia 3
IL - Israele 3
UZ - Uzbekistan 3
VE - Venezuela 3
ZA - Sudafrica 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BD - Bangladesh 2
BG - Bulgaria 2
BO - Bolivia 2
CO - Colombia 2
CZ - Repubblica Ceca 2
EG - Egitto 2
KE - Kenya 2
KZ - Kazakistan 2
LU - Lussemburgo 2
MX - Messico 2
PE - Perù 2
RS - Serbia 2
TN - Tunisia 2
BN - Brunei Darussalam 1
CY - Cipro 1
EC - Ecuador 1
GE - Georgia 1
IM - Isola di Man 1
IS - Islanda 1
JP - Giappone 1
KG - Kirghizistan 1
LB - Libano 1
LV - Lettonia 1
MN - Mongolia 1
MY - Malesia 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
PH - Filippine 1
PY - Paraguay 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
Totale 11.588
Salva come PNG Salva come JPEG
Città #
Chandler 858
Fairfield 706
Des Moines 687
Jacksonville 528
Ashburn 481
Dublin 386
Wilmington 378
Boardman 317
Hong Kong 308
Woodbridge 306
Seattle 269
Houston 247
New York 202
Cambridge 195
Singapore 185
Lawrence 160
Princeton 160
San Mateo 153
Ann Arbor 126
Abidjan 124
The Dalles 107
Centro 98
San Diego 78
Moscow 75
Pune 56
Washington 40
Turin 38
London 35
Beijing 34
Marche 33
Los Angeles 32
Helsinki 27
Guangzhou 26
Redmond 26
Dallas 25
Falls Church 22
Shanghai 21
Ancona 20
Norwalk 20
Wuhan 19
São Paulo 18
Brussels 16
Jiaxing 14
Rome 12
Kilburn 11
Wuxi 9
Hounslow 8
Izmir 8
Squinzano 8
Warsaw 8
Fayetteville 7
Nanjing 7
Prescot 7
Rio de Janeiro 7
Belo Horizonte 6
Chengdu 6
Chiswick 6
Guarulhos 6
Munich 6
Porto 6
Strasbourg 6
Yiwu 6
Brasília 5
Campinas 5
Chicago 5
Council Bluffs 5
Porto Alegre 5
San Francisco 5
Santa Clara 5
Seoul 5
Tolentino 5
Zhengzhou 5
Buffalo 4
Edinburgh 4
Frankfurt am Main 4
Milan 4
Nuremberg 4
Phoenix 4
Shenzhen 4
Sorocaba 4
Turku 4
Wandsworth 4
Berlin 3
Brooklyn 3
Clifton 3
Curitiba 3
Jinhua 3
Macerata 3
Marano di Valpolicella 3
Modena 3
Osasco 3
Portland 3
Redwood City 3
Rio Branco 3
Stockholm 3
São Luís 3
Tashkent 3
Torre Del Greco 3
Alfenas 2
Atlanta 2
Totale 7.938
Salva come PNG Salva come JPEG
Nome #
Designing novel immunocombinations in metastatic renal cell carcinoma 164
Germline and somatic mutations in prostate cancer: Focus on defective DNA repair, PARP inhibitors and immunotherapy 133
Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications 127
Thymic neoplasms: an update on the use of chemotherapy and new targeted therapies. A literature review. 123
Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in Renal Cell Carcinoma 117
Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy 116
Lgr5 expression, cancer stem cells and pancreatic cancer: Results from biological and computational analyses 115
Microbiome and cancers, with focus on genitourinary tumors 114
Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients 113
BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: Molecular diagnostics and possible targets for personalized therapies 112
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 111
Metabolic phenotype of bladder cancer 111
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 110
Predicting future cancer burden in the United States by artificial neural networks 107
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in clear cell renal cell carcinoma patients 106
Neutrophil‑to‑lymphocyte ratio may be associated with the outcome in patients with prostate cancer 103
Exploring the Spectrum of Kidney Ciliopathies 103
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications 101
KRAS mutation status is associated with specific pattern of genes expression in pancreatic adenocarcinoma 100
Toll like receptors and pancreatic diseases: From a pathogenetic mechanism to a therapeutic target 98
Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer Therapy 98
Oligometastases in Genitourinary Tumors: Recent Insights and Future Molecular Diagnostic Approach 98
Is There a Role for Immunotherapy in Prostate Cancer? 98
Metabolic Alterations in Renal and Prostate Cancer 96
Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies 95
Pd-l1 inhibitors for the treatment of prostate cancer 95
Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer 92
HER family receptor expression and prognosis in pancreatic cancer 91
Hyponatremia in cancer patients: Time for a new approach 91
Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers 90
PD-1 blockade therapy in renal cell carcinoma: current studies and future promises 89
KRAS: To be or not to be targeted? Biologic and computational analyses in pancreatic adenocarcinoma 89
Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies 89
Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy 89
Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib 89
Pseudocarcinomatous hyperplasia associated with primary lymphoma in the urinary bladder: a case report 88
Risk of hyponatraemia in cancer patients treated with targeted therapies: A systematic review and meta-analysis of clinical trials 87
RAS genes in colorectal carcinoma: Pathogenesis, testing guidelines and treatment implications 87
Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter 87
Urinary catheters and biofilm formation 86
New prostate cancer targets for diagnosis, imaging, and therapy: Focus on prostate-specific membrane antigen 86
Molecular characterization of testicular germ cell tumors using tissue microdissection 86
Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus 85
High CTLA-4 expression correlates with poor prognosis in thymoma patients 85
Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution 84
Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer 84
Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer 83
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 83
Biomarkers for VEGF-Targeted Therapy in Renal Cell Carcinoma: Critical Review of Level of Evidence and Up to Date 81
Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms 80
An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer 80
New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents? 80
PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: the Role of PD-L1 Assay 80
The route to personalized medicine in bladder cancer: where do we stand? 80
Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy 79
IMPACT OF VEGF, VEGFR, PDGFR, HIF AND ERCC1 GENE POLYMORPHISMS ON THYMIC MALIGNANCIES OUTCOME 79
Combining radiotherapy with immunocheckpoint inhibitors or CAR-T in Renal Cell Carcinoma 79
Immunotherapy in renal cell carcinoma: latest evidence and clinical implications 79
Present and future of personalized medicine in adult genitourinary tumors 78
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors 78
Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer 77
Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives. 76
Emerging concepts on drug resistance in bladder cancer: Implications for future strategies 76
Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients 76
Epigenetic modulations and lineage plasticity in advanced prostate cancer 76
Quick steps toward precision medicine in renal cell carcinoma 76
Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular Perspectives 76
Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. 75
Metabolic alterations in renal cell carcinoma 75
AR-V7 and prostate cancer: The watershed for treatment selection? 75
Trattamento del carcinoma del pancreas. Attualità e prospettive 75
Immunotherapy and radiation therapy in renal cell carcinoma 75
TNM staging towards a personalized approach in metastatic urothelial carcinoma: What will the future be like?-a narrative review 75
Emerging Immunotargets and Immunotherapies in Prostate Cancer 74
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 74
Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies 74
The role of obesity in renal cell carcinoma patients: Clinical-pathological implications 74
Genitourinary tumors: Update on molecular biomarkers for diagnosis, prognosis and prediction of response to therapy 74
The identification of immunological biomarkers in kidney cancers 74
Treating prostate cancer by antibody-drug conjugates 74
Re: Epithelial-to-mesenchymal transition in renal neoplasms 73
Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors 73
Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Protein in Urothelial Cell Carcinoma of Human Bladder 72
Role of STAT3 pathway in genitourinary tumors 72
New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials 72
Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States 71
Renal Cell Carcinoma: genomic landscape and clinical implications 70
Bone targeting agents in patients with metastatic prostate cancer: State of the art 70
Editorial: Emerging biomarkers in genitourinary tumors 69
An update on investigational therapies that target STAT3 for the treatment of cancer 69
Bladder cancer: molecular determinants of personalized therapy 69
Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: A systematic review and meta-analysis 68
The origin of prostate metastases: emerging insights 67
Long Non-coding RNAs in prostate cancer with emphasis on second chromosome locus associated with prostate-1 expression 67
Healthcare cost of HER2-positive and negative breast tumors in the United States (2012–2035) 67
Key role of obesity in genitourinary tumors with emphasis on urothelial and prostate cancers 67
Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies 67
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma 66
Exploring small extracellular vesicles for precision medicine in prostate cancer 66
Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. 65
Totale 8.618
Salva come PNG Salva come JPEG
Categoria #
all - tutte 72.041
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 72.041
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020158 0 0 0 0 0 0 0 0 0 0 30 128
2020/20212.580 140 151 236 15 242 512 268 200 196 277 273 70
2021/20221.351 200 208 40 24 26 142 33 65 104 118 134 257
2022/20232.870 240 271 149 214 151 879 6 156 586 13 152 53
2023/20241.405 239 34 99 163 204 362 30 41 4 30 17 182
2024/20252.065 323 207 32 17 103 89 240 93 590 240 131 0
Totale 11.848